Komori
Perseus Proteomics (4882) · RiskMitigated

Risk of Share Price Decline Due to Sales of Shares Held by Venture Capital Firms

First written in FY2021. 4 of 5 entries say "Mitigated", first in FY2022. Latest entry: FY2025.

5entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021MitigatedFY2022 – FY20252021: 120212022: 120222023: 120232024: 120242025: 12025
Same theme, other companies
Deterioration in Supply and Demand from Share Sales by Venture Capital Firms and OthersA theme 62 companies write about · 62 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2019: 2 of 13 companies on the "Worse" side.

20 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 62 companies compared. The sentences above are computed from all 62.
Full recordFilings, disclosures and news, newest first
  1. FY2025MitigatedAnnual report

    「As of the end of the fiscal year, the aggregate proportion of the company's issued shares held by venture capital firms and investment partnerships formed by venture capital firms, collectively referred to below as “VCs and other entities,” was approximately 4.6% as of 31 March 2025.」

    The proportion held by VCs and other entities fell from 9.6% in the previous fiscal year to approximately 4.6%. The risk itself of a deterioration in supply and demand and a share price decline due to sales continues.
  2. FY2024MitigatedAnnual report

    「As of the end of the fiscal year, venture capital firms and investment partnerships formed by venture capital firms, collectively referred to below as “VCs and other entities,” held 9.6% of the company's issued shares.」

    The proportion held by VCs and other entities fell from 23.9% in the previous fiscal year to 9.6%. The risk of a deterioration in supply and demand and a share price decline due to sales continues to be disclosed.
  3. FY2023MitigatedAnnual report

    「As of the end of the fiscal year, venture capital firms and investment partnerships formed by venture capital firms held 23.9% of the company's issued shares.」

    The proportion held by VCs and other entities fell from 25.4% in the previous fiscal year to 23.9%. The risk of a deterioration in supply and demand and a share price decline due to sales continues to be disclosed.
  4. FY2022MitigatedAnnual report

    「As of the end of the fiscal year, venture capital firms and investment partnerships formed by venture capital firms, collectively referred to below as “VCs and other entities,” held 25.4% of the company's issued shares.」

    The proportion held by VCs and other entities fell from 52.3% in the previous fiscal year to 25.4%, while the possibility of a share price decline due to post-listing sales continues to be disclosed.
  5. FY2021First statedAnnual report

    「As of the end of the fiscal year, venture capital firms and investment partnerships formed by venture capital firms, collectively referred to below as “VCs and other entities,” held 52.3% of the company's issued shares.」

    This indicates that share sales by VCs and other entities after the listing could lead to a deterioration in short-term supply and demand and a decline in the market price.
Moved together

"Expansion of antibody research support and sales of antibodies and reagents" moved the same way as this thread, in the same document, in 4 of its 5 moves.

443333★123456
  1. ★This thread
  2. 1Expansion of antibody research support and sales of antibodies and reagents4×
  3. 2Dependence on Fujifilm and Customer Concentration4×
  4. 3Drug Discovery through Joint Research with Universities and Research Institutions and Expansion of Contract Research3×
  5. 4Research on expanding PPMX-T003 indications to hematologic and solid cancers3×
  6. 5Development of the PPMX-T004 ADC and licensing to FUJIFILM3×
  7. 6Securing R&D Funding Through Partnerships, Grants and Investor Fundraising3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Perseus Proteomics yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Share Price Decline Due to Sales of Shares Held by Venture Capital Firms | Perseus Proteomics Inc. (4882) | Komori